HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

Kura Oncology (NASDAQ:KURA) fell ~9% in regular trading on Thursday even as the cancer drug developer and its partner Kyowa Kirin (OTCPK:KYKOF) announced a mid-stage trial win for their jointly ...

KOMET-001 trial met its primary endpoint for ziftomenib in R/R NPM1-mutant AML, with statistically significant CR and CRh rates. Kura plans to submit an NDA for ziftomenib in Q2 2025 and initiate ...

After successful FDA interactions in part facilitated by BTD, Kura announced that it is on track to submit an NDA to the FDA for ziftomenib for the treatment of patients with R/R NPM1-mutant AML ...

The KOMET-001 trial, which tested ziftomenib in patients with NPM1-mutant AML, achieved statistical significance on its primary efficacy endpoint. All the news that moves the needle in pharma and ...

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial in patients with relapsed/refractory ...

AML 作为一种侵袭性血液恶性肿瘤，具有显著的生物学和临床异质性，精准的风险分层对优化治疗效果、减少治疗相关并发症至关重要。目前，细胞遗传学变化和基因突变已被用于风险分层，其中 NPM1 和 FLT3-ITD 是 AML 患者中最常见的复发性基因突变 。然而，对这些突变进行分子检测存在诸多挑战，如不同机构资源和实验室基础设施差异大，限制了检测的可及性，延长了检测周转时间。

Phenotypic and genotypic characterization of an inherited CEBPA germline mutation in a case of pediatric acute myeloid leukemia. (A) The heterozygous germline CEBPA (p.Val119Alafs*42) variant in ...